1175526-48-3

Basic information

• Product Name: 3,5-dichlorobenzyl carbonochloridate
• Synonyms: 3,5-dichlorobenzyl carbonochloridate
• CAS NO: 1175526-48-3
• Molecular Weight: 239.485
• Mol File: 1175526-48-3.mol

Chemical Properties

• CAS DataBase Reference: 3,5-dichlorobenzyl carbonochloridate(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-dichlorobenzyl carbonochloridate(1175526-48-3)
• EPA Substance Registry System: 3,5-dichlorobenzyl carbonochloridate(1175526-48-3)

Safety Data

• Hazardous Substances Data: 1175526-48-3(Hazardous Substances Data)

Upstream product

• 75-44-5 phosgene 
• 60211-57-6 3,5-dichlorobenzyl alcohol 

Downstream Products

• 1175526-49-4 (2'-{[(3,5-Dichloro-benzyloxycarbonyl)-ethyl-amino]-methyl}-6-methoxy-4'-trifluoromethyl-biphenyl-3-yl)-acetic acid methyl ester 
• 1613513-05-5 3,5-Dichlorobenzyl 2-(2-((tert-butoxycarbonyl)amino)ethyl)morpholine-4-carboxylate 
• 1246639-95-1 3,5-dichlorobenzyl-4-aminopiperidine-1-carboxylate hydrochloride 
• 1613513-18-0 3,5-dichlorobenzyl 4-(3-(1H-1,2,3-triazol-4-yl)propanamido)piperidine-1-carboxylate 
• 1613513-14-6 3,5-dichlorobenzyl 4-( 4-(1H-1,2,3-triazol-4-yl)butanamido )piperidine-1-carboxylate 
• 1613512-87-0 3,5-dichlorobenzyl 4-(2-((tert-butoxycarbonyl)amino)ethyl)piperidine-1-carboxylate 
• 1246639-94-0 3,5-dichlorobenzyl-4-((tert-butoxycarbonyl)amino)piperidine-1-carboxylate 
• 1613513-78-2 3,5-dichlorobenzyl 8-azabicyclo[3.2.1]octan-3-ylcarbamate hydrochloride 
• 1613512-94-9 3,5-dichlorobenzyl 4-((3-(3-hydroxyisoxazol-5-yl)propanamido)methyl)-2-methylpiperidine-1-carboxylate 

Relevant articles and documents

An insight into the anticancer potential of carbamates and thiocarbamates of 10-demethoxy-10-methylaminocolchicine

Colchicine shows very high antimitotic activity, therefore, it is used as a lead compound for generation of new anticancer agents. In the hope of developing novel, useful drugs with more favourable pharmacological profiles, a series of doubly modified colchicine derivatives has been designed, synthesized and characterized. These novel carbamate or thiocarbamate derivatives of 10-demethoxy-10-methylaminocolchicine have been tested for their antiproliferative activity against four human cancer cell lines. Additionally, their mode of action has been evaluated as colchicine binding site inhibitors, using molecular docking studies. Most of the tested compounds showed greater cytotoxicity (IC50 in a low nanomolar range) and were characterized by a higher selectivity index than standard chemotherapeutics such as cisplatin and doxorubicin as well as unmodified colchicine. Their pharmacological use in cancer therapy could possibly be accomplished with lower dosages and result in less acute toxicity problems than in the case of colchicine. In addition, we present a QSAR model for predicting the antiproliferative activity of doubly modified derivatives for two tumour cell lines.

Discovery and optimization of a biphenylacetic acid series of prostaglandin D2 receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis

Biphenylacetic acid (5) was identified through a library screen as an inhibitor of the prostaglandin D2 receptor DP2 (CRTH2). Optimization for potency and pharmacokinetic properties led to a series of selective CRTH2 antagonists. Compounds demonstrated potency in a human DP2 binding assay and a human whole blood eosinophil shape change assay, as well as good oral bioavailability in rat and dog, and efficacy in a mouse model of allergic rhinitis following oral dosing.

N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS

Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGD2 receptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.